of Applikon Biotechnology in Switzerland. Applikon Biotechnology (part of Getinge since January 2020) is a world leader in developing and supplying advanced
bioreactor systems from laboratory scale to production scale. Together, we focus on supplying the best product offering for our customers now and in the long-term future. The portfolio of Applikon Biotechnology ranges from very small mini-bioreactors to large volume cultivation systems. Whether used for laboratory applications, good manufacturing practices, or the full scale-up process from lab to production, together, we have the right solution.
In a time when a lot of medical research focus is dedicated to vaccines, Getinge is launching a new, holistic system approach for preparation of multi-use bioreactors from Applikon, which was acquired by the Swedish medtech company in 2020.
To control the pandemic SARS-CoV-2 outbreak, rapid development of a COVID-19 vaccine is needed as well as serological tests to determine whether or not someone has contracted the virus and has built up immunity. The baculovirus-insect cell expression system can be used to produce the SARS-CoV-2 spike protein for vaccine and serological test applications. To produce sufficient amounts of spike protein in a relatively short period of time, rapid screening for optimal process conditions is of utmost importance.
We will get in touch with you as soon as possible.